MALAT1: Difference between revisions
Jump to navigation
Jump to search
m (→Further reading: task, replaced: journal = PloS → journal = PLoS using AWB) |
imported>OAbot m (Open access bot: add pmc identifier to citation with #oabot.) |
||
| Line 35: | Line 35: | ||
== As a target for the treatment of cancer == | == As a target for the treatment of cancer == | ||
Genetic loss or systemic knockdown of Malat1 using [[Antisense therapy|antisense oligonucleotides (ASO)]] in the mouse mammary carcinoma model results in slower tumor growth accompanied by significant differentiation into cystic tumors and a reduction in metastasis. At the molecular level, the ASO-Malat1 hybrid stimulates a naturally occurring cellular enzyme that degrades the Malat1 lncRNA. Malat1 knockdown results in alterations in gene expression and changes in splicing patterns of genes involved in differentiation and protumorigenic signaling pathways. Metastatic tumors have a dependency on Malat1—they can't thrive without it. And very importantly, only the cancer cells seem to require it. In so far as MALAT1 has been identified to be involved in tumorigenesis of various types of cancer such as lung cancer, pancreatic cancer, cervical cancer Malat1 ASOs represent a potential therapy for inhibiting such cancers progression.<ref name="pmid26701265">{{cite journal | vauthors = Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, Kim Y, MacLeod AR, Krainer AR, Norton L, Brogi E, Egeblad M, Spector DL | title = Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss | journal = Genes & Development | volume = 30 | issue = 1 | pages = 34–51 | date = January 2016 | pmid = 26701265 | doi = 10.1101/gad.270959.115 }}</ref> | Genetic loss or systemic knockdown of Malat1 using [[Antisense therapy|antisense oligonucleotides (ASO)]] in the mouse mammary carcinoma model results in slower tumor growth accompanied by significant differentiation into cystic tumors and a reduction in metastasis. At the molecular level, the ASO-Malat1 hybrid stimulates a naturally occurring cellular enzyme that degrades the Malat1 lncRNA. Malat1 knockdown results in alterations in gene expression and changes in splicing patterns of genes involved in differentiation and protumorigenic signaling pathways. Metastatic tumors have a dependency on Malat1—they can't thrive without it. And very importantly, only the cancer cells seem to require it. In so far as MALAT1 has been identified to be involved in tumorigenesis of various types of cancer such as lung cancer, pancreatic cancer, cervical cancer Malat1 ASOs represent a potential therapy for inhibiting such cancers progression.<ref name="pmid26701265">{{cite journal | vauthors = Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, Kim Y, MacLeod AR, Krainer AR, Norton L, Brogi E, Egeblad M, Spector DL | title = Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss | journal = Genes & Development | volume = 30 | issue = 1 | pages = 34–51 | date = January 2016 | pmid = 26701265 | doi = 10.1101/gad.270959.115 | pmc = 4701977 }}</ref> | ||
== See also == | == See also == | ||
| Line 57: | Line 57: | ||
* {{cite journal | vauthors = Wilusz JE, Freier SM, Spector DL | title = 3' end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA | journal = Cell | volume = 135 | issue = 5 | pages = 919–32 | date = November 2008 | pmid = 19041754 | pmc = 2722846 | doi = 10.1016/j.cell.2008.10.012 }} | * {{cite journal | vauthors = Wilusz JE, Freier SM, Spector DL | title = 3' end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA | journal = Cell | volume = 135 | issue = 5 | pages = 919–32 | date = November 2008 | pmid = 19041754 | pmc = 2722846 | doi = 10.1016/j.cell.2008.10.012 }} | ||
* {{cite journal | vauthors = Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Müller-Tidow C | title = MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer | journal = Oncogene | volume = 22 | issue = 39 | pages = 8031–41 | date = September 2003 | pmid = 12970751 | doi = 10.1038/sj.onc.1206928 }} | * {{cite journal | vauthors = Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Müller-Tidow C | title = MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer | journal = Oncogene | volume = 22 | issue = 39 | pages = 8031–41 | date = September 2003 | pmid = 12970751 | doi = 10.1038/sj.onc.1206928 }} | ||
* {{cite journal | vauthors = Miyagawa R, Tano K, Mizuno R, Nakamura Y, Ijiri K, Rakwal R, Shibato J, Masuo Y, Mayeda A, Hirose T, Akimitsu N | title = Identification of cis- and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles | journal = RNA | volume = 18 | issue = 4 | pages = 738–51 | date = April 2012 | pmid = 22355166 | doi = 10.1261/rna.028639.111 }} | * {{cite journal | vauthors = Miyagawa R, Tano K, Mizuno R, Nakamura Y, Ijiri K, Rakwal R, Shibato J, Masuo Y, Mayeda A, Hirose T, Akimitsu N | title = Identification of cis- and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles | journal = RNA | volume = 18 | issue = 4 | pages = 738–51 | date = April 2012 | pmid = 22355166 | doi = 10.1261/rna.028639.111 | pmc = 3312561 }} | ||
{{refend}} | {{refend}} | ||
== External links == | == External links == | ||
* [https://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=607924 OMIM page for MALAT1] | * [https://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=607924 OMIM page for MALAT1] | ||
* [ | * [https://www.genenames.org/data/hgnc_data.php?hgnc_id=29665 HGNC page for MALAT1] | ||
* {{Rfam|id=RF01871|name=Metastasis associated lung adenocarcinoma transcript 1}} | * {{Rfam|id=RF01871|name=Metastasis associated lung adenocarcinoma transcript 1}} | ||
[[Category:Non-coding RNA]] | [[Category:Non-coding RNA]] | ||
Latest revision as of 06:22, 23 May 2018
| VALUE_ERROR (nil) | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Aliases | |||||||
| External IDs | GeneCards: [1] | ||||||
| Orthologs | |||||||
| Species | Human | Mouse | |||||
| Entrez |
|
| |||||
| Ensembl |
|
| |||||
| UniProt |
|
| |||||
| RefSeq (mRNA) |
|
| |||||
| RefSeq (protein) |
|
| |||||
| Location (UCSC) | n/a | n/a | |||||
| PubMed search | n/a | n/a | |||||
| Wikidata | |||||||
| |||||||
| Conserved secondary structure in Metastasis associated lung adenocarcinoma transcript 1 | |
|---|---|
| File:MALAT1 secondary structure.jpg Predicted secondary structure and sequence conservation of MALAT1 | |
| Identifiers | |
| Symbol | MALAT1 |
| Rfam | RF01871 |
| Other data | |
| RNA type | Gene; |
| Domain(s) | Eukaryota; |
| GO | 2000147 |
| SO | 0001263 |
| PDB structures | PDBe |
MALAT 1 (metastasis associated lung adenocarcinoma transcript 1) also known as NEAT2 (noncoding nuclear-enriched abundant transcript 2) is a large, infrequently spliced non-coding RNA, which is highly conserved amongst mammals and highly expressed in the nucleus.[1] MALAT1 was identified in multiple types of physiological processes, such as alternative splicing, nuclear organization, epigenetic modulating of gene expression, and a number of evidences indicate that MALAT1 also closely relate to various pathological processes, ranging from diabetes complications to cancers.[2][3] It regulates the expression of metastasis-associated genes.[4] It also positively regulates cell motility via the transcriptional and/or post-transcriptional regulation of motility-related genes.[5] MALAT1 may play a role in temperature-dependent sex determination in the Red-eared slider turtle (Trachemys scripta).[6]
Expression in alcoholic brains
Transcripts of MALAT1 are significantly increased in the cerebellum of human alcoholics, as well as in similar regions of rat brains after the withdrawal of ethanol vapours. This alcohol-induced upregulation of MALAT1 may be responsible for differential expression of a number of proteins which contribute to ethanol tolerance and dependency in humans.[7]
Prognostic potential in cancer
The implication of MALAT1 RNA in the pathology of various cancers has been documented.[3] Elevated MALAT1 expression is correlated with poor overall survival in various types of cancer, suggesting that this gene is a prognostic factor for different types of cancer.[8][9]
As a target for the treatment of cancer
Genetic loss or systemic knockdown of Malat1 using antisense oligonucleotides (ASO) in the mouse mammary carcinoma model results in slower tumor growth accompanied by significant differentiation into cystic tumors and a reduction in metastasis. At the molecular level, the ASO-Malat1 hybrid stimulates a naturally occurring cellular enzyme that degrades the Malat1 lncRNA. Malat1 knockdown results in alterations in gene expression and changes in splicing patterns of genes involved in differentiation and protumorigenic signaling pathways. Metastatic tumors have a dependency on Malat1—they can't thrive without it. And very importantly, only the cancer cells seem to require it. In so far as MALAT1 has been identified to be involved in tumorigenesis of various types of cancer such as lung cancer, pancreatic cancer, cervical cancer Malat1 ASOs represent a potential therapy for inhibiting such cancers progression.[10]
See also
References
- ↑ Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess A (2007). "A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains". BMC Genomics. 8: 39. doi:10.1186/1471-2164-8-39. PMC 1800850. PMID 17270048. open access publication – free to read
- ↑ Wu Y, Huang C, Meng X, Li J (2015). "Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease". Current Pharmaceutical Design. 21 (34): 5017–28. doi:10.2174/1381612821666150724115625. PMID 26205289.
- ↑ 3.0 3.1 Yoshimoto R, Mayeda A, Yoshida M, Nakagawa S (January 2016). "MALAT1 long non-coding RNA in cancer". Biochimica et Biophysica Acta. 1859 (1): 192–9. doi:10.1016/j.bbagrm.2015.09.012. PMID 26434412.
- ↑ Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zörnig M, MacLeod AR, Spector DL, Diederichs S (February 2013). "The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells". Cancer Research. 73 (3): 1180–9. doi:10.1158/0008-5472.CAN-12-2850. PMC 3589741. PMID 23243023.
- ↑ Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, Ijiri K, Akimitsu N (November 2010). "MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes". FEBS Letters. 584 (22): 4575–80. doi:10.1016/j.febslet.2010.10.008. PMID 20937273.
- ↑ Chojnowski JL, Braun EL (Jul 15, 2012). "An unbiased approach to identify genes involved in development in a turtle with temperature-dependent sex determination". BMC Genomics. 13: 308. doi:10.1186/1471-2164-13-308. PMC 3434017. PMID 22793670.
- ↑ Kryger R, Fan L, Wilce PA, Jaquet V (November 2012). "MALAT-1, a non protein-coding RNA is upregulated in the cerebellum, hippocampus and brain stem of human alcoholics". Alcohol. 46 (7): 629–34. doi:10.1016/j.alcohol.2012.04.002. PMID 22560368.
- ↑ Tian X, Xu G (2015). "Clinical value of lncRNA MALAT1 as a prognostic marker in human cancer: systematic review and meta-analysis". BMJ Open. 5 (9): e008653. doi:10.1136/bmjopen-2015-008653. PMC 4593150. PMID 26423854. open access publication – free to read
- ↑ Wei Y, Niu B (2015). "Role of MALAT1 as a Prognostic Factor for Survival in Various Cancers: A Systematic Review of the Literature with Meta-Analysis". Disease Markers. 2015: 164635. doi:10.1155/2015/164635. PMC 4572489. PMID 26420912.
- ↑ Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, Kim Y, MacLeod AR, Krainer AR, Norton L, Brogi E, Egeblad M, Spector DL (January 2016). "Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss". Genes & Development. 30 (1): 34–51. doi:10.1101/gad.270959.115. PMC 4701977. PMID 26701265.
Further reading
- Guo F, Li Y, Liu Y, Wang J, Li Y, Li G (March 2010). "Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion". Acta Biochimica et Biophysica Sinica. 42 (3): 224–9. doi:10.1093/abbs/gmq008. PMID 20213048.
- Ji Q, Liu X, Fu X, Zhang L, Sui H, Zhou L, Sun J, Cai J, Qin J, Ren J, Li Q (Nov 2013). "Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway". PLoS One. 8 (11): e78700. doi:10.1371/journal.pone.0078700. open access publication – free to read
- Tseng JJ, Hsieh YT, Hsu SL, Chou MM (November 2009). "Metastasis associated lung adenocarcinoma transcript 1 is up-regulated in placenta previa increta/percreta and strongly associated with trophoblast-like cell invasion in vitro". Molecular Human Reproduction. 15 (11): 725–31. doi:10.1093/molehr/gap071. PMID 19690017.
- van Asseldonk M, Schepens M, de Bruijn D, Janssen B, Merkx G, Geurts van Kessel A (May 2000). "Construction of a 350-kb sequence-ready 11q13 cosmid contig encompassing the markers D11S4933 and D11S546: mapping of 11 genes and 3 tumor-associated translocation breakpoints". Genomics. 66 (1): 35–42. doi:10.1006/geno.2000.6194. PMID 10843802.
- Koshimizu TA, Fujiwara Y, Sakai N, Shibata K, Tsuchiya H (March 2010). "Oxytocin stimulates expression of a noncoding RNA tumor marker in a human neuroblastoma cell line". Life Sciences. 86 (11–12): 455–60. doi:10.1016/j.lfs.2010.02.001. PMID 20149803.
- Guru SC, Agarwal SK, Manickam P, Olufemi SE, Crabtree JS, Weisemann JM, Kester MB, Kim YS, Wang Y, Emmert-Buck MR, Liotta LA, Spiegel AM, Boguski MS, Roe BA, Collins FS, Marx SJ, Burns L, Chandrasekharappa SC (July 1997). "A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus". Genome Research. 7 (7): 725–35. doi:10.1101/gr.7.7.725. PMC 310681. PMID 9253601.
- Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, Blencowe BJ, Prasanth SG, Prasanth KV (September 2010). "The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation". Molecular Cell. 39 (6): 925–38. doi:10.1016/j.molcel.2010.08.011. PMID 20797886.
- Kuiper RP, Schepens M, Thijssen J, van Asseldonk M, van den Berg E, Bridge J, Schuuring E, Schoenmakers EF, van Kessel AG (July 2003). "Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution". Human Molecular Genetics. 12 (14): 1661–9. doi:10.1093/hmg/ddg178. PMID 12837690.
- Yamada K, Kano J, Tsunoda H, Yoshikawa H, Okubo C, Ishiyama T, Noguchi M (February 2006). "Phenotypic characterization of endometrial stromal sarcoma of the uterus". Cancer Science. 97 (2): 106–12. doi:10.1111/j.1349-7006.2006.00147.x. PMID 16441420.
- Wilusz JE, Freier SM, Spector DL (November 2008). "3' end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA". Cell. 135 (5): 919–32. doi:10.1016/j.cell.2008.10.012. PMC 2722846. PMID 19041754.
- Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Müller-Tidow C (September 2003). "MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer". Oncogene. 22 (39): 8031–41. doi:10.1038/sj.onc.1206928. PMID 12970751.
- Miyagawa R, Tano K, Mizuno R, Nakamura Y, Ijiri K, Rakwal R, Shibato J, Masuo Y, Mayeda A, Hirose T, Akimitsu N (April 2012). "Identification of cis- and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles". RNA. 18 (4): 738–51. doi:10.1261/rna.028639.111. PMC 3312561. PMID 22355166.